| October 8, 2021
|
| October 19, 2021
|
| April 24, 2024
|
| October 14, 2021
|
| August 1, 2025 (Final data collection date for primary outcome measure)
|
| Progression Free Survival (PFS) [ Time Frame: Up to 5 years ] PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first.
|
| Progression Free Survival (PFS) [ Time Frame: Up to 5 years and 2 months ] PFS is defined as the time from the date of randomization to the date of first documented disease progression, as defined in the International Myeloma Working Group (IMWG) criteria, or death due to any cause, whichever occurs first.
|
|
|
- Overall Response (Partial Response [PR] or Better) [ Time Frame: Up to 5 years ]
Overall response (PR or better) is defined as participants who have a PR or better per IMWG criteria.
- Very Good Partial Response (VGPR) or Better [ Time Frame: Up to 5 years ]
VGPR or better is defined as participants who achieve a VGPR or better response per IMWG criteria.
- Complete Response (CR) or Better [ Time Frame: Up to 5 years ]
CR or better is defined as participants who achieve a CR or better response per IMWG criteria.
- Minimal Residual Disease (MRD)-negativity [ Time Frame: Up to 5 years ]
MRD-negativity is defined as participants who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy.
- Progression Free Survival on Next-line Therapy (PFS2) [ Time Frame: Up to 5 years ]
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.
- Overall Survival (OS) [ Time Frame: Up to 5 years ]
OS is measured from the date of randomization to the date of the participant's death.
- Time to Next Treatment (TTNT) [ Time Frame: Up to 5 years ]
TTNT is defined as the interval time from randomization to the start of subsequent antimyeloma treatment.
- Duration of Response [ Time Frame: Up to 5 years ]
Duration of response will be calculated among responders (with a PR or better response) from the date of initial documentation of a response (PR or better) to the date of first documented evidence of progressive disease according to the IMWG response criteria, or death due to any cause, whichever occurs first.
- Number of Participants with Adverse Events (AEs) by Severity [ Time Frame: Up to 5 years ]
Number of participants with AEs by Severity will be reported.
- Serum Concentration of Teclistamab [ Time Frame: Up to 5 years ]
Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive method.
- Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Daratumumab [ Time Frame: Up to 5 years ]
Number of participants with ADAs to teclistamab and daratumumab will be reported.
- Time to Worsening of Symptoms [ Time Frame: Up to 5 years ]
Time to worsening is measured as the interval from the date of randomization to the start date of meaningful change.
- Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) [ Time Frame: Baseline up to 5 years ]
The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score [ Time Frame: Baseline up to 5 years ]
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Measurement Information System Short Form v2.0 - Physical Function 8c (PROMIS PF 8c) [ Time Frame: Baseline up to 5 years ]
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. Higher overall score indicates more sleep disturbance.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ) [ Time Frame: Baseline up to 6 months ]
The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) [ Time Frame: Baseline up to 5 years ]
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient Global Impression - Severity (PGI-S) [ Time Frame: Baseline up to 5 years ]
The PGIS contains 2 questions on how the participant would currently rate severity of symptoms and impacts with a 7-day recall period. The response options are presented as a 5-point verbal rating scale from 1="none" to 5="very severe."
- PFS in Participants with High-risk Molecular Features [ Time Frame: Up to 5 years ]
PFS in participants with high-risk molecular features will be reported.
- Depth of Response in Participants in High-risk Molecular Features [ Time Frame: Up to 5 years ]
Depth of response in participants in high-risk molecular features will be reported.
|
- Overall Response (Partial Response [PR] or Better) [ Time Frame: Up to 5 years and 2 months ]
Overall response (PR or better) is defined as participants who have a PR or better per IMWG criteria.
- Very Good Partial Response (VGPR) or Better [ Time Frame: Up to 5 years and 2 months ]
VGPR or better is defined as participants who achieve a VGPR or better response per IMWG criteria.
- Complete Response (CR) or Better [ Time Frame: Up to 5 years and 2 months ]
CR or better is defined as participants who achieve a CR or better response per IMWG criteria.
- Minimal Residual Disease (MRD)-negativity [ Time Frame: Up to 5 years and 2 months ]
MRD-negativity is defined as participants who achieve MRD negativity at a threshold of 10^-5 at any timepoint after the date of randomization and before disease progression or start of subsequent antimyeloma therapy.
- Progression Free Survival on Next-line Therapy (PFS2) [ Time Frame: Up to 5 years and 2 months ]
PFS2 is defined as the time interval between the date of randomization and date of event, which is defined as progressive disease as assessed by investigator on the first subsequent line of antimyeloma therapy, or death from any cause, whichever occurs first.
- Overall Survival (OS) [ Time Frame: Up to 5 years and 2 months ]
OS is measured from the date of randomization to the date of the participant's death.
- Time to Next Treatment (TTNT) [ Time Frame: Up to 5 years and 2 months ]
TTNT is defined as the interval time from randomization to the start of subsequent antimyeloma treatment.
- Number of Participants with Adverse Events (AEs) by Severity [ Time Frame: Up to 5 years and 2 months ]
Number of participants with AEs by Severity will be reported.
- Serum Concentration of Teclistamab [ Time Frame: Up to 5 years and 2 months ]
Serum samples will be analyzed to determine concentrations of teclistamab using a validated, specific, and sensitive method.
- Number of Participants with Anti-drug Antibodies (ADAs) to Teclistamab and Daratumumab [ Time Frame: Up to 5 years and 2 months ]
Number of participants with ADAs to teclistamab and daratumumab will be reported.
- Time to Worsening of Symptoms [ Time Frame: Up to 5 years and 2 months ]
Time to worsening is measured as the interval from the date of randomization to the start date of meaningful change.
- Change from Baseline in Symptoms, Functioning, and Overall Health-related Quality of Life (HRQoL) as Assessed by European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC-QLQ-C30) [ Time Frame: Baseline up to 5 years and 2 months ]
The EORTC-QLQ-C30 Version 3 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, and social), 1 global health status scale, 3 symptom scales (pain, fatigue, and nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties). The responses are reported using a verbal and numeric rating scales. The item and scale scores are transformed to a 0 to 100 scale. A high scale score represents a higher response level. Thus, a high score for a functional scale represents a high/healthy level of functioning and a high score for the global health status represents high HRQoL, but a high score for a symptom scale/item represents a high level of symptomatology/problems.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Multiple Myeloma Symptom and Impact Questionnaire (MySIm-Q) Scale Score [ Time Frame: Baseline up to 5 years and 2 months ]
The MySIm-Q is a disease-specific PRO assessment complementary to the EORTC-QLQ-C30. It includes 17 items resulting in a symptom subscale and an impact subscale. The recall period is the "past 7 days", and responses are reported on a 5-point verbal rating scale.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Measurement Information System Short Form v2.0 - Physical Function 8c (PROMIS PF 8c) [ Time Frame: Baseline up to 5 years and 2 months ]
The PROMIS-SD is used to assess self-reported perceptions of sleep quality, sleep depth and restoration associated with sleep. The 8-item short form will be used in this study, in which responses are scored 1 to 5 for each item. Higher overall score indicates more sleep disturbance.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient-reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE ) [ Time Frame: Baseline up to 6 months ]
The National Cancer Institute's (NCI's) PRO-CTCAE is an item library of common adverse events experienced by people with cancer that are appropriate for self-reporting of treatment tolerability. Each symptom selected for inclusion can be rated by up to 3 attributes characterizing the presence/frequency, severity, and/or interference of the AEs. It ranges from 0 to 4 with higher scores indicating higher frequency or greater severity/impact.
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by EuroQol Five Dimension Questionnaire 5-Level (EQ-5D-5L) [ Time Frame: Baseline up to 5 years and 2 months ]
The EQ-5D-5L is a generic measure of health status. The EQ-5D-5L is a 5-item questionnaire that assesses 5 domains including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression plus a visual analog scale rating "health today" with anchors ranging from 0 (worst imaginable health state) to 100 (best imaginable health state).
- Change from Baseline in Symptoms, Functioning, and Overall HRQoL as Assessed by Patient Global Impression - Severity (PGI-S) [ Time Frame: Baseline up to 5 years and 2 months ]
The PGIS contains 2 questions on how the participant would currently rate severity of symptoms and impacts with a 7-day recall period. The response options are presented as a 5-point verbal rating scale from 1="none" to 5="very severe."
- PFS in Participants with High-risk Molecular Features [ Time Frame: Up to 5 years and 2 months ]
PFS in participants with high-risk molecular features will be reported.
- Depth of Response in Participants in High-risk Molecular Features [ Time Frame: Up to 5 years and 2 months ]
Depth of response in participants in high-risk molecular features will be reported.
|
| Not Provided
|
| Not Provided
|
| |
| A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
|
| A Phase 3 Randomized Study Comparing Teclistamab in Combination With Daratumumab SC (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma
|
| The purpose of this study is to compare the efficacy of teclistamab daratumumab (Tec-Dara) with daratumumab subcutaneously (SC) in combination with pomalidomide and dexamethasone (DPd) or daratumumab SC in combination with bortezomib and dexamethasone (DVd).
|
| Teclistamab is a novel B-cell maturation antigen (BCMA) bispecific antibody that is being evaluated to treat participants with multiple myeloma, an incurable malignant plasma cell disorder. The primary hypothesis of this study is that Tec-Dara will significantly improve progression free survival (PFS) compared with investigator's choice of DPd/DVd in participants with relapsed refractory multiple myeloma. Approximately 560 participants will be randomly assigned in a 1:1 ratio to receive either Tec-Dara (Arm A) or investigator's choice of DPd/DVd (Arm B). The study will be conducted in 3 phases: Screening Phase, Treatment Phase, and Follow-up Phase. Participants will be treated until disease progression, unacceptable toxicity, or other reasons to discontinue the study. Disease evaluation will occur every cycle. Safety will be assessed throughout the study. Efficacy will be assessed using International Myeloma Working Group (IMWG) criteria. The overall duration of the study will be approximately 5 years.
|
| Interventional
|
| Phase 3
|
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
|
| Multiple Myeloma
|
- Drug: Daratumumab
Daratumumab will be administered SC injection.
- Drug: Pomalidomide
Pomalidomide will be administered orally.
- Drug: Dexamethasone
Dexamethasone will be administered orally or intravenously.
- Drug: Bortezomib
Bortezomib will be administered SC injection.
- Drug: Teclistamab
Teclistamab will be administered SC injection.
Other Name: JNJ-64007957
|
- Experimental: Arm A: Teclistamab-daratumumab (Tec-Dara)
Participants will receive teclistamab and daratumumab by subcutaneous (SC) injection. Step-up doses of teclistamab will be given prior to the first full dose.
Interventions:
- Drug: Daratumumab
- Drug: Teclistamab
- Experimental: Arm B: DPd or DVd
Participants will be randomized either to daratumumab, pomalidomide, dexamethasone (DPd) treatment to receive daratumumab SC injection; pomalidomide orally; dexamethasone orally or intravenously, or to Daratumumab, Bortezomib, Dexamethasone (DVd) treatment to receive daratumumab SC injection; bortezomib SC injection, and dexamethasone orally or intravenously.
Interventions:
- Drug: Daratumumab
- Drug: Pomalidomide
- Drug: Dexamethasone
- Drug: Bortezomib
|
| Not Provided
|
| |
| Active, not recruiting
|
| 587
|
| 560
|
| December 8, 2028
|
| August 1, 2025 (Final data collection date for primary outcome measure)
|
Inclusion Criteria:
- Documented multiple myeloma as defined by the criteria: a. multiple myeloma diagnosis according to the International Myeloma Working Group (IMWG) diagnostic criteria, b. measurable disease at screening as defined by any of the following: 1) serum M-protein level greater than or equal to (>=) 0.5 gram per deciliter (g/dL); or 2) urine M-protein level >=200 milligrams (mg)/24 hours; or 3) serum immunoglobulin free light chain >=10 mg/dL and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Received 1 to 3 prior line(s) of antimyeloma therapy including a proteasome inhibitor (PI) and lenalidomide; a. participants who have received only 1 line of prior line of antimyeloma therapy must be lenalidomide refractory. Stable disease or progression on or within 60 days of the last dose of lenalidomide given as maintenance will meet this criterion
- Documented evidence of progressive disease based on investigator's determination of response by IMWG criteria on or after their last regimen
- Have an eastern cooperative oncology group (ECOG) performance status score of 0, 1, or 2 at screening and prior to the start of administration of study treatment
- Have clinical laboratory values within the specified range
Exclusion Criteria:
|
| Sexes Eligible for Study: |
All |
|
| 18 Years and older (Adult, Older Adult)
|
| No
|
| Contact information is only displayed when the study is recruiting subjects
|
| Argentina, Belgium, Brazil, Canada, China, Denmark, France, Germany, Greece, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Sweden, Taiwan, Turkey, United Kingdom, United States
|
| Ukraine
|
| |
| NCT05083169
|
CR109049
2020-004742-11 ( EudraCT Number )
64007957MMY3001 ( Other Identifier: Janssen Research & Development, LLC )
2023-503441-55-00 ( Registry Identifier: EUCT number )
|
| Yes
|
| Studies a U.S. FDA-regulated Drug Product: |
Yes |
| Studies a U.S. FDA-regulated Device Product: |
No |
|
| Plan to Share IPD: |
Yes |
| Plan Description: |
The data sharing policy of the Janssen Pharmaceutical Companies of Johnson and Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) project site at yoda.yale.edu |
| URL: |
https://www.janssen.com/clinical-trials/transparency |
|
| Janssen Research & Development, LLC
|
| Same as current
|
| Janssen Research & Development, LLC
|
| Same as current
|
| Not Provided
|
| Study Director: |
Janssen Research & Development, LLC Clinical Trial |
Janssen Research & Development, LLC |
|
| Janssen Research & Development, LLC
|
| April 2024
|
